Podcasts about breakthroughs

This week we're in hygge mode, uncovering traumas in our generational home with the host of This Had Oscar Buzz, Joe Reid! One of the breakout Oscar films of the year is Joachim Trier's Sentimental Value, a warm, realist Norwegian film about a difficult but brilliant director (Stellan Skarsgard), his two daughters (Renate Reinsve and Inga Ibsdotter Lilleaas), and an American actress cast in the auteur's new film (Elle Fanning). All four performances earned Oscar nominations, along with nominations for Best Picture, Best International Feature, Best Film Editing, and Best Original Screenplay. Sentimental Value also highlights a recurring phenomenon in Hollywood, wherein the Academy will pass over a director's breakout film but shower the follow-up with nominations. In Trier's case, his previous film The Worst Person in the World received nominations for Best International Film and Original Screenplay but, in our opinion, deserved many more. We try to break down how and why this happens, whether films about filmmaking have an innate appeal to Oscar voters, how Fanning's star power helps bridge the international gap for voters, and the film itself, including its deft intermingling of artistic expression and sublimated generational trauma.  With Joe's guidance, we also check in on some of the Oscar-buzziest films of the year that didn't pan out, check in on the state of the acting category race and some potential upsets, and celebrate The Secret Agent's breakout star Tânia Maria and her new role as Burger King spokeswoman. Sign up for Check Book, the Blank Check newsletter featuring even more “real nerdy shit” to feed your pop culture obsession. Dossier excerpts, film biz AND burger reports, and even more exclusive content you won't want to miss out on. Join our Patreon for franchise commentaries and bonus episodes. Follow us @blankcheckpod on Twitter, Instagram, Threads and Facebook!  Buy some real nerdy merch Connect with other Blankies on our Reddit or Discord For anything else, check out BlankCheckPod.com Learn more about your ad choices. Visit megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices

This year’s Academy Awards will include the first-ever Oscar for Achievement in Casting. It’s the first new category in 25 years, since Best Animated Feature was added in 2001 (which inaugural award was won by Shrek). Casting, though, is seen as kind of an illusive, inscrutable art form. We feel like we can separate out the writing and the editing and the costuming and the directing from a thing. But the cast kind of IS the thing a lot of the time, right? It’s kind of inextricable from the thing, it feels like. This hour: a look at the art of casting. GUESTS: Mellini Kantayya: An actor and writer and the author of Actor. Writer. Whatever. (essays on my rise to the top of the bottom of the entertainment industry) John Frank Levey: A four-time Emmy Award-winning casting director and the author of Right for the Role: Breakdowns, Breakups and Breakthroughs from 35 Years of Casting Iconic TV Shows Connor Ratliff: An actor, writer, and comedian and the creator and host of Dead Eyes Michael Schulman: A staff writer at The New Yorker and the author of Oscar Wars: A History of Hollywood in Gold, Sweat, and Tears Support the show: http://www.wnpr.org/donateSee omnystudio.com/listener for privacy information.

Stormy seas battered the hatches of the SS Sparks & Recreation as news of a shuffle bug hits the Realms! Join the crew as they talk through this surprising discovery and what it means for players.The storm doesn't stop there – more bug talk follows as the crew discusses the latest update before breaking down which balance changes actually landed.Finally, a breakthrough has been made on Hero Helper development, and Tuff brings the latest from behind the scenes. All that and more on this episode, thanks for listening! WWYD: 7:08Bugs: 21:34Balance: 46:59(Hero-helper) Breakthrough: 1:41:56Community Round-up: 1:47:15Taps, Scrap, and Good-byes: 2:04:10Hero Realms is a fantasy-themed expandable deckbuilding game from Wise Wizard Games.Hosts: Chris "DblDubz" Walberg, Cooper "Filtrophobe" Fitzpatrick, and John "Tuff" LabellaProducer: Chris WalbergHero Helper: https://hero-helper.com/Realms Rising: https://www.realmsrising.comYou can find the WWYD screenshots for this episode here: https://www.realmsrising.com/podcast/sparks-and-recreation-96-bugs-balance-and-breakthroughsPatreon: https://patreon.com/sparksandrecHyperGeometric Calculator: https://aetherhub.com/Apps/HyperGeometricCommunity Tournaments & Events Primer (+ signup links): https://www.realmsrising.com/community-events/Realms Rising Discord: https://discord.gg/8pTxKqzFDcContact S&R: contact@sparks-and-recreation.comSupport Sparks & Rec: https://hero-helper.com/support-usSparks & Recreation Website: https://www.realmsrising.com/sparks-and-recreation/Thank you so much to Level 12 Hero Sarah T., Warden Slayer, as well as Level 7 Hero Nudeltulpe!Specific songs used in this episode were:Intro/Outro Music: "Uplifting Orchestra Pack" by GoodBunny. (Under the Music Standard License)Licensed under Creative Commons BY Attribution 4.0 License Hosted on Acast. See acast.com/privacy for more information.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a compelling array of advancements and strategic shifts that are shaping the healthcare landscape across the globe.In recent times, the pharmaceutical and biotech sectors have showcased remarkable resilience and innovation, driving forward with significant scientific breakthroughs and clinical trial results. A standout achievement comes from Novo Nordisk, whose recent Phase 2 trial results for its triple agonist targeting obesity reported a remarkable weight loss of up to 19.7% in patients over 24 weeks. This promising development positions Novo Nordisk as a formidable contender in the obesity treatment market, potentially affecting giants like Eli Lilly. With obesity being a significant global health challenge, these findings underscore the potential of multi-targeted approaches in managing this complex condition.Regulatory landscapes continue to evolve, with pivotal approvals marking milestones for therapies targeting rare diseases. Immedica Pharma's Loargys received FDA approval for treating hyperargininemia associated with arginase 1 deficiency, highlighting perseverance in overcoming regulatory hurdles after a prior rejection. Additionally, Sanofi and Regeneron's Dupixent achieved its ninth FDA approval, underscoring its versatile potential across multiple indications. These approvals not only reflect regulatory progress but also emphasize the critical role of persistence in drug development.Ethical considerations remain at the forefront of industry discussions, particularly highlighted by Novartis' settlement in a lawsuit concerning the use of Henrietta Lacks' cells without consent. This resolution underscores ongoing ethical challenges within biomedical research, emphasizing the need for ethical vigilance as companies increasingly rely on human-derived materials.Significant business trends are shaping strategic directions within the industry. Pfizer's acquisition of marketing rights for Sciwind's GLP-1 receptor agonist in China exemplifies a calculated move to dominate the obesity treatment market. This strategic acquisition allows Pfizer to leverage China's vast market potential for type 2 diabetes medications and positions it favorably for future weight loss treatments.On the manufacturing front, AbbVie has made substantial investments in U.S. infrastructure, committing $380 million to new North Chicago API plants as part of a decade-long strategy to inject $100 billion into U.S. operations. This initiative highlights a commitment to bolstering domestic production capabilities amidst global supply chain uncertainties.The complexities of drug development are further illustrated by Roche's decision to halt the development of Enspryng for Duchenne muscular dystrophy due to unsatisfactory progress. This shift in focus reflects the inherent challenges of drug repurposing and the necessity of robust clinical evidence to support new indications.Geopolitical factors also play a significant role in shaping industry dynamics, with recent U.S. Supreme Court decisions impacting international trade agreements. Such geopolitical influences can significantly affect pharmaceutical companies' operations and strategic planning.The collaboration between Astellas and Vir Biotechnology reflects another significant trend in strategic partnerships within the industry. Their $1.7 billion deal centered on a novel bispecific T-cell engager for prostate cancer underscores the growing importance of immuno-oncology and innovative approaches to targeting hard-to-treat cancers.The regulatory front continues to see transformative changes with the FDA unveiling draft guidance for a new approval pathway tailored for bespoke gene-editing therapies. This initiative could expedite personalized genetic treatments and transform patSupport the show

It's EV News Briefly for Tuesday 24 February 2026, everything you need to know in less than 5 minutes if you haven't got time for the full show.Patreon supporters fund this show, get the episodes ad free, as soon as they're ready and are part of the EV News Daily Community. You can be like them by clicking here: https://www.patreon.com/EVNewsDailyDALLAS SUPPLIER CLAIMS THREE-MINUTE LITHIUM-ION CHARGE https://evne.ws/3OuytZC DONUT LAB BATTERY TESTS HIT 11C CHARGING https://evne.ws/4qSEkW0 SLATE AUTO PICKUP SPOTTED CHARGING IN MICHIGAN https://evne.ws/4rzzgXN SAMSUNG SDI TARGETS LITHIUM-METAL BATTERY WEAK SPOT https://evne.ws/4qUkJEO KIA BRINGS PV5 ELECTRIC VAN TO CANADA https://evne.ws/3MLHNri ALLEGO CUTS UBER DRIVERS' DC CHARGING COSTS https://evne.ws/4kSUBst BMW TO DROP LEVEL 3 ON 7 SERIES https://evne.ws/46lma86 FORD PLANS 2026 PIKES PEAK MACH-E RETURN https://evne.ws/4kT1Qkf DENZA B8 BECOMES AUSTRALIA'S HEAVIEST PASSENGER SUV https://evne.ws/4s80QuT DIESEL TRUCKS AND BUSES COST AUSTRALIA A$6.2BN A YEAR https://evne.ws/3ZWPpdF PHOENIX CONTACT LAUNCHES 500 KW NACS, CCS CABLES https://evne.ws/4tOmFlb SOLAR PANELS BOOST SHEEP AND POWER NEAR DUBBO https://evne.ws/4rxDKxT

In this episode of Making Sense, Kate Finlayson, Global head of the FICC Market Structure and Liquidity Strategy, is joined by Sandy Kaul, Executive Vice President and Head of Innovation at Franklin Templeton, and Scott Lucas, head of Markets Digital Assets at J.P. Morgan. Together, they explore the rapid advancements in blockchain technology, and discussing what's changed, what's credible, and what institutional investors should be thinking about as market structure evolves. Sandy and Scott, who also serve as co-chairs of the CFTC's Digital Assets Subcommittee, share insights on blockchain adoption milestones, regulatory developments, the convergence of traditional and decentralized finance, and the future of interoperability and market infrastructure.   This episode was recorded on February 10, 2026.  The views expressed in this podcast may not necessarily reflect the views of JPMorgan Chase & Co, and its affiliates, together J.P. Morgan, and do not constitute research or recommendation advice or an offer or a solicitation to buy or sell any security or financial instrument. They are not issued by Research but are a solicitation under CFTC Rule 1.71. Referenced products and services in this podcast may not be suitable for you, and may not be available in all jurisdictions. J.P. Morgan may make markets and trade as principal in securities and other asset classes and financial products that may have been discussed. The FICC market structure publications, or to one, newsletters, mentioned in this podcast are available for J.P. Morgan clients. Please contact your J.P. Morgan sales representative should you wish to receive these. For additional disclaimers and regulatory disclosures, please visit www.jpmorgan.com/disclosures Copyright 2026 JPMorgan Chase & Company. All rights reserved.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world.Today, we delve into the latest from an industry that continues to break new ground in both scientific innovation and regulatory landscapes. The pharmaceutical and biotech sectors are buzzing with activity as companies engage in bold strategies and face significant challenges in their quest for groundbreaking treatments.A recent event illustrating the high-stakes nature of this industry involves Novo Nordisk and its decision to conduct a head-to-head clinical trial for Cagrisema against Eli Lilly's Zepbound. This trial, which typically occurs post-approval, was conducted at the candidate stage. Novo Nordisk aimed to establish market dominance by proving superiority early on. However, the trial did not go as planned, with Cagrisema failing to outperform Zepbound. This outcome serves as a reminder of the competitive dynamics in early-stage testing and the strategic risks companies are willing to take in their bid for market leadership.Meanwhile, Gilead Sciences has made a bold move with a $7.8 billion investment in Arcellx, focusing on CAR T-cell therapy. This investment highlights Gilead's commitment to advanced cancer treatments, particularly Anito-cel for relapsed or refractory multiple myeloma. CAR T-cell therapies involve modifying a patient's T-cells to target cancer cells more effectively, representing a significant leap forward in oncological treatments. With an FDA decision anticipated by December 2026, Gilead's investment underscores its strategic focus on transformative therapies that could redefine cancer care.In legal news, Regenxbio has secured a notable victory against Sarepta Therapeutics regarding adeno-associated virus (AAV) technology patents. The appeals court ruling in favor of Regenxbio emphasizes the intricate nature of patent law in biotechnology, where innovations often intersect with naturally occurring biological processes. This decision not only solidifies Regenxbio's intellectual property but also sets a precedent for future patent disputes within the sector.On the regulatory front, Vanda Pharmaceuticals has rebounded from previous setbacks by securing FDA approval for drugs targeting bipolar disorder and schizophrenia. This achievement marks a promising shift for Vanda, demonstrating resilience and adaptability in redirecting focus towards neuropsychiatric conditions. The approval expands therapeutic options for these complex disorders, addressing long-standing unmet needs within mental health care.Despite these advancements, some areas continue to face hurdles. Gene therapies like Casgevy and Lyfgenia for sickle cell disease have struggled to gain traction two years post-launch. These therapies promise a one-time cure by correcting genetic defects but have encountered challenges in achieving widespread adoption. The difficulties reflect broader issues in transitioning from clinical success to market viability.Moreover, workforce reductions at major companies such as Bristol-Myers Squibb and Catalent signal structural changes within the industry. These layoffs may indicate shifts in strategic focus or responses to evolving market pressures as companies strive for efficiency and innovation.Regulatory practices are also undergoing scrutiny as the FDA considers defaulting to single clinical trial requirements for drug approvals. While this move could streamline development processes, it raises concerns about maintaining rigorous safety standards—a balance that remains crucial as companies push to bring innovative treatments to market swiftly yet safely.The dynamic nature of this industry is further highlighted by Candel Therapeutics' recent $100 million royalty deal aimed at launching its prostate cancer treatment. This strategic move underscores growing interest in innovative oncology solutions thaSupport the show

… There are always NEW LEVELS in God available to us… GREATER ANOINTINGS, MIRACLES, HEALINGS, FINANCIAL BREAKTHROUGHS, SALVATIONS, INCREASE ….

You might remember Alexandra Paul as one of the stars of Baywatch or the Tom Hanks-Dan Aykroyd Dragnet film. You may not have realized that as a child and on to her long trip through the worlds of modeling and Hollywood, she was bingeing and purging and dealing with severe eating disorders. She tells us about her relationship with sugar and what food meant emotionally. Then we're joined by Dr. Cynthia Bulik, one of the top experts on eating disorders in the world today, to talk about remarkable progress in understanding the genetic components of eating disorders. Rather than blame family (especially mothers), peer pressure, or fashion culture, Dr. Bulik says some people are much more prone to developing eating disorders due to the genes they happened to get. You can be part of her research by visiting EDGI2.org. Thank you to all our listeners who support the show as monthly members of Maximum Fun. Check out our I'm Glad You're Here and Depresh Mode merchandise at the brand new merch website MaxFunStore.com! Hey, remember, you're part of Depresh Mode and we want to hear what you want to hear about. What guests and issues would you like to have covered in a future episode? Write us at depreshmode@maximumfun.org. Depresh Mode is on BlueSky, Instagram, Substack, and you can join our Preshies Facebook group.  Help is available right away. The National Suicide Prevention Lifeline: 988 or 1-800-273-8255, 1-800-273-TALK Crisis Text Line: Text HOME to 741741. International suicide hotline numbers available here: https://www.opencounseling.com/suicide-hotlines  

Why do revolutionary ideas so often come from outsiders? Do good scientists sometimes crowd out great ones? Do we still have room for scientific cowboys? And what is the relationship between national security and modern science? Are scientists participants in a larger game they barely see? What if the most important ideas are the ones you’re not allowed to hear about? From Crick and Watson to nuclear bombs and AI, today we’ll cover it all with physicist, mathematician, and iconoclast Eric Weinstein.

Deterred but Determined | Burdens to Breakthroughs | Nehemiah 4 by CityLight Church

Pisces season is the pre-beginning of the zodiac year. It is the liminal space before Aries, when things are still forming, dissolving, clarifying, and choosing. In this episode, I walk through what Pisces season tends to stir up, and why this particular Pisces season matters in a bigger, longer arc.The headline is the Saturn–Neptune conjunction at 0° Aries (Feb 20). We have been building toward this since last summer. Neptune brings the dream, the vision, the imagination. Saturn brings the structure, the commitment, the foundation that makes something real. I talk about how I'm working with it in practice: writing it down, making a plan, building scaffolding, and taking tangible steps so the vision actually has somewhere to land.From there, we move into the rest of Pisces season's timeline: eclipse season, Mercury retrograde in Pisces, Mars entering Pisces, and the Virgo lunar eclipse that highlights the Pisces–Virgo polarity (oneness vs discernment, spirituality vs practicality, intuition vs the calendar). I close with the pivot point that changes the temperature entirely: March 20, the astrological new year, when the Sun enters Aries and Mercury stations direct, lighting up one of the most Aries-activated days I have ever seen on a chart.Episode timestamps00:00 Pisces Season Begins: Big Transits, Eclipses & the ‘Grand Finale' Energy00:48 What Pisces Really Means: Endings, Pre-Birth, Purpose & Interconnectedness03:11 Saturn–Neptune at 0° Aries: Turning Dreams Into Reality (How to Work With It)06:03 Practical Manifestation Tips: Lists, Plans, and Building Saturn Scaffolding09:10 Key Dates Kick Off: Mars–Chiron + Venus Trine Jupiter (Healing Meets Ease)12:36 Mercury Retrograde in Pisces: Shadow Clues, Re-words, and Water-Sign Caution14:58 Feb 27 Power Day: Mars Square Uranus + Sun Conj North Node + Mercury Conj Venus19:10 Mars Enters Pisces: Motivation in the Mist & Acting With Compassion22:24 March 3 Lunar Eclipse in Virgo: Pisces vs Virgo, Discernment, and Jupiter Release Valve27:33 Eclipse Family Themes: Looking Up Bernadette Brady's Take28:07 Mercury Retrograde + Eclipse Season Wrap-Up: Slow Down & Communicate29:55 Early March Sweet Spots: Venus–Uranus & Sun–Jupiter Good Vibes31:16 Venus Enters Aries: Passion, Risk-Taking & Relationship Heat32:35 March 7–8 Clarity & Magnetism: Mercury Cazimi + Saturn–Neptune Activation35:24 Transformation & Forward Motion: Venus–Pluto + Jupiter Stations Direct38:24 Fated Action Points: Mars–North Node & Mercury–Mars During Retrograde39:45 March 18–19 Tension, Breakthroughs & Healing Closure (Chiron–Eris)42:58 Astrological New Year Ignition: Sun into Aries + Mercury Direct45:45 Chart Rundown & The Most Aries Day Ever: 7 Planets in Aries (March 20)50:14 Final Takeaways: Choosing the First Step Into Your New IdentityWork with meJournée (membership): Join hereCosmic Consult (1:1): Book here — we'll look at what's being activated in your chart and map the next right stepWhere to find mecosmicmoves.com

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the dynamic landscape of these industries, exploring significant regulatory shifts, scientific breakthroughs, and strategic corporate maneuvers that are shaping the future of healthcare.The pharmaceutical and biotech sectors are currently navigating a period of profound transition. Recent regulatory developments have captured attention, particularly the U.S. Supreme Court's decision to overturn emergency tariffs imposed by the previous administration. This ruling is pivotal as it alleviates financial pressures on the industry, allowing companies to redirect their resources towards innovation and development. It underscores the interconnectedness of global supply chains and highlights the importance of stable regulatory environments for fostering industry growth.In a notable advancement within oncology, AstraZeneca has achieved FDA approval for its combination therapy of Calquence and Venclexta as an all-oral regimen for first-line chronic lymphocytic leukemia (CLL). This approval not only positions AstraZeneca competitively in the BTK inhibitor market but also signifies a shift towards more patient-friendly treatment regimens. By simplifying therapy, this development promises to enhance patient compliance and improve outcomes, challenging existing standards in CLL care.Meanwhile, internal challenges at the Centers for Disease Control and Prevention have led to a postponement of a critical vaccine advisory panel meeting. This delay occurs amid evolving vaccine policies that have sparked debate within the public health community, potentially impacting immunization strategies and initiatives aimed at bolstering public health.Corporate governance within the industry is also experiencing shifts. Novo Nordisk has nominated two industry veterans to its board as part of an ongoing strategy to align leadership with evolving business objectives. Similarly, Roche is contemplating divesting its once-blockbuster antibiotic Rocephin in response to competitive pressures from generics in Europe. These moves reflect a broader industry trend where companies are re-evaluating their portfolios to better respond to market dynamics and patent expirations.Novartis is making strategic changes as well by selling its stake in Novartis India Limited while maintaining separate commercial and R&D interests in the region. This action highlights a growing trend among pharmaceutical giants towards streamlining operations and focusing on high-growth areas—a strategy aimed at maximizing resource allocation efficiency.Despite narrowly missing a $1 billion revenue target for 2025, Madrigal Pharmaceuticals remains optimistic about the growth prospects of its drug Rezdiifra within the metabolic dysfunction-associated steatohepatitis (MASH) market. The company anticipates further expansion driven by unmet medical needs, underscoring the competitive dynamics within this therapeutic area.In personnel movements that could influence strategic directions, Daiichi Sankyo has appointed former Novartis CMO John Tsai as head of its R&D division. His expertise is expected to bolster Daiichi's focus on oncology and other critical therapeutic areas, potentially accelerating innovation within their drug development pipeline.Meanwhile, Manus Bio has secured a $15 million contract with the U.S. government for domestic supply of shikimic acid, an essential component for producing Tamiflu. This contract highlights efforts to strengthen domestic pharmaceutical supply chains amid global uncertainties—a crucial consideration for ensuring medication availability during crises.In clinical research, a setback was observed with Grail's Galleri cancer blood test trial failing to meet its primary endpoint in collaboration with the NHS. The resulting decline in GrailSupport the show

In the final week of Breakthroughs and Bequests, as part of Vision 2026, we unpack how God's blessings for "me" involves "we". Support the show

Gregory Zuckerman concludes by crediting American finance for enabling these scientific breakthroughs and expressing optimism that mRNA technology will soon tackle cancer and other illnesses. 8

join wall-e's tech briefing for friday, february 20th, covering the latest developments in technology: google's gemini pro model 3.1: highlighting its enhanced language processing capabilities and success in independent benchmarks, this next-gen ai model is set to redefine real knowledge work. atm jackpotting surge: the fbi reports a significant rise in atm attacks using malware like ploutus, leading to $20 million in losses this year alone. nvidia's expansion in india: partnering with venture firms to support ai startups, nvidia is strengthening its footprint in the indian tech ecosystem. openai's funding milestone: nearing a $100 billion funding round with major investors, this push seeks to enhance openai's growth and edge toward profitability. redwood materials scale-up: expanding its energy storage business with new labs, redwood responds to growing demand from ai data centers and renewable energy sectors. tune in tomorrow for more tech news updates!

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of transformative events reshaping the industry landscape, from scientific breakthroughs to regulatory shifts and strategic corporate maneuvers.Let's start with Insmed's Brinsupri, a newly approved respiratory therapy that has captured attention with its projected $1 billion in sales by 2026. This ambitious forecast is grounded in Brinsupri's robust clinical efficacy and the increasing demand for innovative respiratory treatments. This development reflects a broader industry trend where targeted therapies are not only improving patient outcomes but also driving significant revenue growth. As respiratory conditions continue to be a major health challenge globally, the success of therapies like Brinsupri underscores the potential for innovation to meet these critical needs.In parallel, Merck is working strategically with its RSV antibody, Enflonsia, seeking a second-season approval to bolster its competitive stance against Sanofi and AstraZeneca's Beyfortus. The race in infant RSV prevention is intense as companies vie to establish dominance in this crucial segment of infectious disease management. Merck's efforts highlight the broader push within the industry to develop preventive measures that could significantly alter public health landscapes by reducing the incidence of severe respiratory illnesses in vulnerable populations.Meanwhile, regulatory scrutiny remains a constant for pharmaceutical companies. The FDA's recent review of Johnson & Johnson's advertising for Tremfya, targeting ulcerative colitis, emphasizes the agency's commitment to ensuring that efficacy claims are both truthful and transparent. This serves as a reminder of the importance of maintaining regulatory compliance and ethical advertising practices within the industry—a critical aspect as companies navigate complex marketing landscapes while ensuring patient trust.Shifts in leadership within key health organizations are also noteworthy. Jay Bhattacharya stepping into the role of acting CDC chief after Jim O'Neill's departure could signal changes in public health policy and research priorities. Such transitions can have profound effects on how emerging health challenges are addressed, potentially influencing everything from vaccine distribution strategies to research funding allocations.As we turn to policy discussions, President Donald Trump's most favored nation drug pricing proposal continues to stir debate. This initiative aims to lower drug prices by benchmarking them against international rates, but it faces resistance from free-market advocates who argue it could stifle pharmaceutical innovation. The ongoing discussion around drug pricing reform is pivotal, as it impacts both patient access to medications and the incentives for companies to invest in new drug development.Strategic realignments in the contract development and manufacturing organization (CDMO) sector are also making headlines. Recipharm's sale of its Israeli API plant to Scinai Immunotherapeutics, alongside a new CDMO partnership, illustrates how companies are optimizing resources to focus on core competencies and expand service offerings. This strategic shift highlights the dynamic nature of CDMOs as they adapt to changing market demands and technological advancements.In Alzheimer's research, there's promising news with a study suggesting that a blood test could predict when symptoms will appear, representing a significant leap forward in early diagnosis and intervention strategies. These advancements offer hope for altering the treatment landscape of neurodegenerative diseases through timely therapeutic interventions that could improve quality of life for patients. However, challenges remain as seen with Johnson & Johnson pausing enrollment in itsSupport the show

Griff Jenkins reports from Arizona on the ongoing Guthrie murder investigation, detailing how investigative genetic genealogy and trace DNA could finally lead to a breakthrough after 19 days with no suspect. He discusses the local community's reaction, forensic methods, and potential timelines for results. Jenkins also previews Washington D.C.'s upcoming State of the Union, including anticipated protests and congressional attendance, highlighting the intersection of local tragedies, national security concerns, and high-profile political events. Hashtags: #GriffJenkins #GuthrieCase #DNAForensics #InvestigativeGenetics #ArizonaNews #StateOfTheUnion #Congress #Protests #NationalSecurity

Tiffay Hoeft owns Minds Matter in Aberdeen. She joins SDPB's Lori Walsh for a conversation about neurofeedback, mindfulness, and how to reduce your risk for dementia.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a wide array of topics, from groundbreaking therapies and strategic corporate moves to regulatory shifts and industry trends shaping the future of healthcare.We begin with Eli Lilly, which is making significant strides with its combined Zepbound and Taltz therapy, showing promising results in the treatment of psoriasis and obesity. This combination therapy, initially successful in psoriatic arthritis, is set to transform treatment protocols by bridging gaps between psoriasis and obesity. This dual-targeting approach highlights a burgeoning trend in the industry: the use of combination therapies to enhance patient outcomes while streamlining treatment regimens. This strategy not only promises better management of interconnected conditions but also reflects a broader industry goal of maximizing therapeutic reach with existing drugs.Novartis is advancing its portfolio with the oral BTK inhibitor, Rhapsido, following a successful Phase 3 trial for a new chronic hives subtype. This development underscores Novartis's commitment to addressing niche markets and unmet medical needs, emphasizing the pharmaceutical industry's focus on expanding the utility of existing drugs. Additionally, Novartis has entered into a notable partnership with Macrocycle Biotech for cardiovascular drug development. This collaboration represents a broader trend where large pharmaceutical companies seek innovative partnerships to expand their therapeutic portfolios through cutting-edge biotech solutions.Meanwhile, Moderna's influenza vaccine submission has been accepted by the FDA after an initial rejection, illustrating a responsive regulatory environment crucial for timely access to vaccines amid potential flu outbreaks.Johnson & Johnson's $1 billion investment plan in the U.S., focusing on cell therapy, aligns with broader industry trends towards personalized medicine and advanced therapeutic approaches. This investment is part of a strategic pivot towards cell and gene therapies that promise to redefine treatment pathways for complex diseases. Similarly, Bayer's $7.25 billion settlement over Roundup litigation shows an industry keen on resolving legal challenges swiftly to refocus efforts on innovation.Regulatory reforms are also gaining attention, with proposals aimed at streamlining FDA processes to enhance drug access and reduce burdens. These reforms could significantly impact drug development timelines and market entry strategies, reflecting an ongoing discourse on balancing regulation with fostering innovation.On a global scale, Stada's €85 million investment in Saudi Arabia points to a strategic move towards enhancing supply chain resilience in the Middle East and North Africa. This aligns with industry trends focusing on regional manufacturing capabilities to ensure drug availability while reducing logistical complexities.A notable example of strategic resource allocation is Eli Lilly's $100 million upfront payment for CSL's IL-6 antibody development rights. This reflects an adaptive approach where initial clinical setbacks are seen as opportunities for new therapeutic ventures rather than dead ends.Turning our attention to Alzheimer's research, Korsana Biosciences has emerged from stealth mode with substantial funding aimed at developing an anti-amyloid antibody capable of crossing the blood-brain barrier. This effort addresses a critical need within Alzheimer's disease treatment—a field marked by intense competition and scientific challenge. Parallelly, IQVIA Biotech highlights the importance of accelerating early-stage interventions for Alzheimer's through data analytics and optimized clinical trials. Such efforts aim to expedite regulatory approvals and bring new therapies to market faster—a trend indicative of leveragSupport the show

Fluent Fiction - Serbian: Snowfall and Breakthroughs: A Hospital's Modern Tale Find the full episode transcript, vocabulary words, and more:fluentfiction.com/sr/episode/2026-02-19-08-38-20-sr Story Transcript:Sr: Снег је тихо падао изнад града, док је у болници владала ужурбаност.En: The snow was gently falling over the city while there was a bustle in the hospital.Sr: Милош, искусан медицински техничар, журио је низ дуги ходник, носећи са собом важне папире.En: Miloš hurried down the long corridor, carrying important papers with him.Sr: Био је узбуђен јер су данас уграђивали нову медицинску опрему која ће помоћи у бољем збрињавању пацијената.En: He was excited because today they were installing new medical equipment that would aid in better patient care.Sr: Јована, млада медицинска техничарка, стајала је поред једног од нових уређаја, пажљиво га изучавајући.En: Jovana, a young medical technician, stood by one of the new devices, carefully studying it.Sr: "Јована, спремна си за данас?En: "Jovana, are you ready for today?"Sr: " упитао је Милош са осмехом.En: Miloš asked with a smile.Sr: "Спремна и узбуђена, Милоше!En: "Ready and excited, Miloše!"Sr: " одговорила је она са светлуцавим очима.En: she replied with sparkling eyes.Sr: "Ово је сјајна прилика да научимо нешто ново.En: "This is a great opportunity to learn something new."Sr: " Док се њих двоје припремали за данашње задатке, Стефан, старији доктор, посматрао је нову опрему са извесним скептицизмом.En: As the two of them prepared for the day's tasks, Stefan, a senior doctor, observed the new equipment with a certain skepticism.Sr: "Зашто нам треба ови нови уређаји?En: "Why do we need these new devices?"Sr: " питао је Стефан гласом који је одавао сумњу.En: Stefan asked with a voice that betrayed doubt.Sr: "Довољно је компликовано и без тога.En: "Things are complicated enough without them."Sr: "Милош је знао да мора уверити Стефана у важност ове технологије.En: Miloš knew he had to convince Stefan of the importance of this technology.Sr: "Стефане, ова опрема ће нам помоћи да будемо ефикаснији и пружимо бољу негу пацијентима.En: "Stefane, this equipment will help us be more efficient and provide better care to patients.Sr: Видећете, сви ћемо брзо научити како да је користимо.En: You'll see, we'll all quickly learn how to use it."Sr: "Током уређивања нове опреме, појавиле су се техничке потешкоће.En: During the setup of the new equipment, technical difficulties arose.Sr: Изненада, стигло је хитно обавештење: критичан пацијент је захтевао тренутну пажњу.En: Suddenly, an urgent notification arrived: a critical patient required immediate attention.Sr: "Морам да поделим задатке," рекао је Милош брзо.En: "I need to assign tasks," Miloš said quickly.Sr: "Јована, иди у собу за хитне случајеве.En: "Jovana, go to the emergency room.Sr: Стефане, ја ћу остати овде да решимо проблем са уређајима.En: Stefane, I'll stay here to resolve the equipment issues."Sr: "Усред техничког хаоса, пацијент је хитно премештен на нову опрему.En: Amid the technical chaos, the patient was quickly transferred to the new equipment.Sr: Милош је пажљиво надгледао поступак, док је Јована спретно ручала новим уређајем.En: Miloš carefully monitored the procedure, while Jovana skillfully handled the new device.Sr: Стефан, иако невољно, морао је признати да нова технологија функционише беспрекорно.En: Stefan, although reluctantly, had to admit that the new technology worked flawlessly.Sr: Пацијент је стаблизован, што је олакшање донело свима.En: The patient was stabilized, bringing relief to everyone.Sr: Милош се осећао поносним на свој тим.En: Miloš felt proud of his team.Sr: Јована је стекла нове вештине, док је Стефан учио да цени савремене иновације у медицини.En: Jovana gained new skills, while Stefan learned to appreciate modern innovations in medicine.Sr: "Добро си урадио, Милоше," признао је Стефан касније тог дана.En: "You did well, Miloše," Stefan admitted later that day.Sr: "Ова опрема заиста може направити разлику.En: "This equipment really can make a difference."Sr: "Напољу је снег наставио да пада, али у болници, немања хитноћа дала је место узајамном поштовању и сарадњи.En: Outside, the snow continued to fall, but in the hospital, the urgency gave way to mutual respect and collaboration. Vocabulary Words:bustle: ужурбаностinstalling: уграђивалиequipment: опремаaid: помоћиtechnician: техничаркаskepticism: скептицизмомbetrayed: одаваоefficiency: ефикаснијиemergency: хитнеnotification: обавештењеassign: поделимamid: усредchaos: хаосаcarefully: пажљивоskillfully: спретноreluctantly: невољноflawlessly: беспрекорноstabilized: стаблизованrelief: олакшањеproud: поносанgained: стеклаappreciate: цениinnovations: иновацијеmutual: узајамномresolve: решимоtransfer: премештенprocedure: поступакurgency: хитноћаcollaboration: сарадњи

Join us this week as Pastor Nate takes us through the first chapter of Nehemiah.

Patrick Bet-David sits down with Dr. Rhonda Patrick to break down biological vs. chronological aging, AI-driven gene therapy and stem-cell breakthroughs, creatine and fasting for brain performance, exercise's role in reversing heart aging and lowering cancer risk, GLP-1 weight-loss debates, anxiety hacks, and the science behind longevity, family, and happiness.------

For pet owners, a diagnosis such as cancer or chronic disease often brings difficult decisions and limited treatment options, many of which involve invasive procedures. While human medicine has advanced significantly, many of these innovations have been slower to reach veterinary care, underscoring the need for more effective and less invasive approaches to animal health. In this episode of Curing with Sound, we speak with Philip Bergman, DVM, MS, PhD, DACVIM-Oncology, Veterinary Program Director at the Focused Ultrasound Foundation. Dr. Bergman oversees Foundation-funded preclinical research and the clinical studies that enroll companion animals, helping to accelerate translational progress across species.  The conversation explores emerging applications of focused ultrasound in veterinary medicine, including its potential role in treating osteosarcoma, glioblastoma, feline diabetes, and other complex conditions. Dr. Bergman also discusses the collaborative One Medicine approach and how it is advancing care for both animals and people.  Discussion highlights: One Medicine Revolution: Companion animals naturally develop many of the same diseases as humans, allowing veterinary research to inform human medicine—and vice versa—through a shared, translational approach. Breakthroughs in Standard of Care: He shares his vision for a “bench-to-bedside-to-kennel” cycle, in which insights from animal clinical trials accelerate human therapies and human breakthroughs inspire new, noninvasive treatment options for pets. The Future of Veterinary Technology: Hear about efforts to develop cost-effective, veterinary-specific focused ultrasound systems designed to bring this technology into everyday clinical practice. EPISODE TRANSCRIPT ---------------------------- QUESTIONS? Email podcast@fusfoundation.org if you have a question or comment about the show, or if you would you like to connect about future guest appearances.  Email info@fusfoundation.org if you have questions about focused ultrasound or the Foundation.  FUSF SOCIAL MEDIA LinkedIn X Facebook Instagram TikTok YouTube FUSF WEBSITE https://www.fusfoundation.org SIGN UP FOR OUR FREE NEWSLETTER https://www.fusfoundation.org/newsletter-signup/ READ THE LATEST NEWSLETTER https://www.fusfoundation.org/the-foundation/news-media/newsletter/ DOWNLOAD "THE TUMOR" BY JOHN GRISHAM (FREE E-BOOK) https://www.fusfoundation.org/read-the-tumor-by-john-grisham/  

In this episode of 'Autism for Badass Moms,' host Rashidah welcomes Kanisha, a 40-year-old registered nurse in Houston and mom to five-year-old Zoë (diagnosed at 2.5, verbal with limited communication), shares her journey from early concerns and self-referral for evaluation to an ADOS-based diagnosis and the therapies that followed. She opens up about balancing full-time work, navigating limited support, starting full-day ABA, and witnessing Zoë's significant progress.At the heart of the conversation is disclosure. Kanisha explains why she told only a small circle at first, choosing privacy over overwhelm and commentary. She reflects on finding community online and encourages moms to move at their own pace, trust their discernment, and protect their peace.In this episode, we talk about:00:00 Welcome to Autism for Badass Moms (Show Intro)00:46 Today's Topic: Who Do You Tell First After an Autism Diagnosis?02:18 Meet Kisha & Zoe: A Diagnosis That Changed Everything04:42 Early Red Flags: 12–18 Months, Speech Concerns & Being Dismissed07:58 Two-Year Turning Point: Sensory Signs & Suspecting Autism11:22 The Daycare Wake-Up Call: Social Struggles & “Final Piece” Moment13:52 Taking Control: ECI, Child Find & Getting Evaluated Without Waiting16:45 Diagnosis & Insurance Hurdles: Fighting for Speech/OT Services20:03 School vs. Daycare Reality: When Half-Day Support Isn't Enough21:44 Choosing ABA: Fear, First Days, and Finally Seeing Progress24:26 Breakthroughs & Reframing the Future: From Level 3 to New Milestones26:16 The Grief After Diagnosis: Mourning Dreams, Milestones, and the Unknown32:27 Who We Told (and Who We Didn't): Processing the Diagnosis35:34 Grief, “What Ifs,” and Preparing for Every Outcome36:53 Protecting Your Child: Privacy, Boundaries, and Unwanted Advice38:56 Finding Your Tribe: Podcasts, Threads, and Support Groups That Get It44:14 Real-Life Logistics: Summer Break, Programs, and Working Full-Time47:36 Advice to New Autism Moms: Tell People at Your Own Pace51:48 What Makes Her Badass + Closing Reflections and How to Connect56:58 Final Takeaway: Discernment, Peace Over Pressure, and Guest Call-OutConnect with Kanisha:Instagram: www.instagram.com/mamanish20Resource shared:YouTube: confessionsofanautismmomIf this episode resonated with you:• Follow the Autism for Badass Moms Podcast on your favorite platform• Leave a review to help other autism moms find this community• Share this episode with a parent who may feel unseen or misunderstoodInstagram: www.instagram.com/theabmpodcastFacebook: www.facebook.com/theabmpodcastYouTube: autismforbadassmoms

Marketing professor Michelangelo Rossi shares with Breakthroughs the research he and Hi! Paris academic Felix Schleff published on Oscar nominations and their impact on movie-goers' expectations. On the eve of the 98th Academy Awards, Rossi describes the overlooked downside of such quality disclosures. He also shares his latest research on the impact that Europe's Digital Markets Act (DMA) has had on consumers using Google Maps. Hosted on Acast. See acast.com/privacy for more information.

In the 3rd week of our Vision 2026 series , Bequests and Breakthroughs, we are challenged to ask the question - "What kind of miraculous provision are we believing God to provide in our lives as we cross over into the Promised Land?"Support the show

Running your clinic with your partner - but feeling out of sync, stuck talking about work nonstop, or quietly building resentment? In this episode of the Grow Your Clinic podcast, we unpack what actually makes working with your spouse work. We dive into the power of regular check-ins, clear roles, and intentional boundaries that protect both the business and the relationship. You'll hear real lessons on avoiding misalignment, structuring productive conversations, setting KPIs, and separating work from personal time - without letting important issues fester. We also explore how to handle money conversations with transparency, create accountability without tension, and why external support can be a game-changer. If you're building a clinic with your partner and want alignment, clarity, and a relationship that thrives alongside the business, this episode lays out the framework.Need to systemise your clinic? Start your free trial of Allie! https://www.allieclinics.com/ In This Episode You'll Learn: 

If you tune in today & feel I want to walk this path more deeply… We're kicking off our Feminine Embodiment Coaching Certification with a special Orientation Week. → We start on 2 March 2026. → You can find all the details here → —------------ If you're drawn to the embodied arts and feel called to support women in deepening into their body's wisdom - vulnerability is a KEY tool to get there. But vulnerability can be hard enough to cultivate in ourselves. Let alone with clients who are resistant (or numb).  So in today's podcast, the second of our Wise Body series exploring the 6 domains of embodiment coaching for women practitioners, we're mapping the architecture of breakthroughs using vulnerability.    In this episode, we geek out on theories of change, prerequisites for vulnerability, how to cultivate action through flow (not force) & my own recent vulnerable questions.  I'll also share THE key question I ask myself when I'm feeling crunchy & confused… and want to crack my heart open with some (constructive) vulnerability.    Hope you enjoy! Jenna   Links from today's episode: 

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we explore a series of significant shifts in the industry, marked by leadership changes, scientific advancements, strategic partnerships, and regulatory challenges.Starting with Sanofi, a notable leadership transition has taken place as Paul Hudson steps down from his role as CEO. Belen Garijo from Merck KGaA has stepped into this pivotal role. Her appointment is part of a broader industry trend toward diversifying leadership, especially with more women leading top-tier pharmaceutical companies. The implications of this shift could be profound for Sanofi, potentially stabilizing its operations and revitalizing its research pipeline. Stakeholders are keenly observing how this new leadership might steer Sanofi through complex market dynamics.In regulatory news, Moderna has encountered a significant hurdle with the FDA declining to review its next-generation mRNA flu vaccine. This decision has sparked an ongoing public dialogue between Moderna and U.S. health regulators, underscoring the complexities involved in navigating regulatory pathways for novel mRNA technologies beyond their initial success with COVID-19 vaccines. The Department of Health and Human Services has supported the FDA's decision, emphasizing the critical importance of meticulous scrutiny when it comes to new vaccine platforms. This development highlights the challenges biotech companies face in ensuring compliance with stringent regulatory standards.Financial updates reveal CSL experiencing a sharp decline in net profits, dropping from $2 billion to $384 million year-over-year. This financial downturn has been linked to strategic missteps or operational inefficiencies within the company, prompting a change in leadership. Such shifts reflect broader challenges faced by companies within the biotech sector as they strive to maintain financial stability amid fluctuating market conditions.In contrast, Alnylam Pharmaceuticals has reported its first profitable year despite underwhelming sales figures for its drug Amvuttra in the ATTR-CM market. This milestone is significant for Alnylam as it demonstrates resilience and the potential to pivot successfully amidst market uncertainties. However, the company will need to remain vigilant about revenue streams and market dynamics moving forward.Turning to advertising strategies, Johnson & Johnson's Tremfya continues to buck industry trends by maintaining a strong presence in television advertising through 2026. This strategy is noteworthy given the general decline in traditional media spending across the industry. J&J's commitment highlights its determination to sustain market share against competitors such as AbbVie's Rinvoq and Skyrizi.On the strategic front, Takeda Pharmaceuticals is consolidating its U.S. operations by reducing its Boston presence. By subleasing over 630,000 square feet of office space, Takeda aims to streamline operations and concentrate resources on key development projects at its new Cambridge hub. This move reflects broader industry trends towards operational efficiency and resource optimization.In clinical advancements, BridgeBio has reached a promising milestone with successful Phase 3 trial results for infigratinib in treating dwarfism. This breakthrough offers new therapeutic options for children affected by this condition and exemplifies ongoing innovations in genetic medicine. The success of this trial positions BridgeBio on a path toward regulatory approval, potentially transforming care for patients with limited treatment options.Agilent has achieved FDA approval for its companion diagnostic test alongside Merck's Keytruda for ovarian cancer treatment. This approval highlights the growing importance of precision medicine in oncology, where tailored treatments based on individual paSupport the show

Wyatt Feltgen chose the hard road.From getting “obliterated” as a 7th grader on varsity to making deep tournament runs as a postseason threat at 120 lbs, Wyatt's journey is about grit, growth, and refusing to quit.In this episode, Jordan sits down with the Florida High standout to talk about:• Falling in love with wrestling after quitting football• Taking tough losses to Steven Palmer and finally breaking through• The grind that changed everything at George Mulligan• The Florida High brotherhood and mentorship from seniors• Capital City Classic battles and postseason expectations• Why young wrestlers need to find “their senior” and stay the courseThis isn't a story about overnight success.It's about staying in the fight long enough to become dangerous.Wyatt Feltgen is just getting started.

Jeff Bellomo welcomes Mark O'Reilly of Shamrock Strategies Professional Coaching for an interesting conversation about what professional coaching is and how it works. As a coach, Mark creates a safe, confidential space that helps his clients maximize their potential by seeing their situation with fresh eyes.   Mark, who is Jeff's professional coach, points to different situations or transitions that might prompt someone to reach for support, especially when they feel stuck, alone, or unsure how to proceed. These situations often include career promotions, the weight of leadership, impending retirement, or even changes at home.  Coaching isn't about advice or quick fixes. Breakthroughs come from gaining clarity and new perspectives that enable you to set goals and move forward with confidence and enthusiasm.   If you want to explore whether coaching would be a good fit for you, contact Mark O'Reilly to learn more about the process and his free, no-obligation consults. Visit www.shamrockstrategiesllc.com   WHAT YOU NEED TO KNOW (00:00) Episode introduction: Mark O'Reilly  (02:25) Transitioning from manager to professional coach  (04:52) The creation of Shamrock Strategies  (06:02) What is coaching and how does it work?   (07:09) Coaching vs. therapy, mentoring, and consulting  (13:57) People who want to become a better version of themselves  (17:13) Coaching for team members and leaders  (19:21) Providing a safe, confidential space  (21:37) Working with multiple members of the same organization  (23:23) Coaching is an investment in people   (24:54) The value of holistic coaching   (28:10) Shamrock Strategies and free, no-obligation consults     ABOUT BELLOMO & ASSOCIATES Jeffrey R. Bellomo, the founder of Bellomo & Associates, is a licensed and certified elder law attorney with a master's degree in taxation and a certificate in estate planning. He explains complex legal and financial topics in easy-to-understand language. Bellomo & Associates is committed to providing education so that what happened to the Bellomo family doesn't happen to your family. We conduct free workshops on estate planning, crisis planning, Medicaid planning, special needs planning, probate administration, and trust administration. Visit our website (https://bellomoassociates.com/) to learn more.   LINKS AND RESOURCES MENTIONED Bellomo & Associates workshops:https://bellomoassociates.com/workshops/ Life Care Planning The Three Secrets of Estate Planning Nuts & Bolts of Medicaid For more information, call us at (717) 845-5390. Connect with Bellomo & Associates on Social Media Tune in Saturdays at 7:30 a.m. Eastern to WSBA radio: https://www.newstalkwsba.com/ X (formerlyTwitter):https://twitter.com/bellomoassoc YouTube: https://www.youtube.com/user/BellomoAssociates Facebook:https://www.facebook.com/bellomoassociates Instagram:https://www.instagram.com/bellomoassociates/ LinkedIn:https://www.linkedin.com/in/bellomoandassociates WAYS TO WORK WITH JEFFREY BELLOMO Contact Us:https://bellomoassociates.com/contact/ Practice areas:https://bellomoassociates.com/practice-areas/    

What drives someone to leave Imperial College, Oxford, and IBM Research to return to India in the 1990s—when few dared—and build a robotics movement from scratch? In this episode of 3 Techies Banter, we sit down with Kavi Arya, the visionary behind e-Yantra and India's pioneering robotics education initiatives. From the challenges of returning to a liberalizing India, to creating robotic kits that empowered thousands of students, to scaling innovation for a nation of 1.4 billion - this conversation is a masterclass in resilience, risk‑taking, and reimagining engineering education. 00:00 – Highlights of the Episode 04:09 – Intro of Kavi Arya 06:40 – Returning to India in the 1990s 11:20 – Tata Research & Family Business 15:30 – Joining IIT Bombay 20:45 – Building Entrepreneurial Culture at IIT 26:10 – Teaching Embedded Systems & Robotics Kits 31:00 – National Mission for Education Using ICT 36:25 – Industry Experience at Mahindra & Mahindra 42:50 – Founding Iyantra 49:15 – Student Projects & Breakthroughs 55:40 – Scaling Robotics Education 01:02:00 – Advanced Training: Drones & Control Systems 01:08:30 – Innovation, Scale & Culture 01:15:00 – Closing Thoughts Discover how: A PhD in embedded systems met India's scarcity mindset. IIT Bombay became the birthplace of hands‑on robotics learning. Students built lemon‑sorting robots, drones, and even autonomous snakes. Scale, culture, and confidence are the true engines of innovation. If you've ever wondered how India can leapfrog into the future of technology, this episode is your blueprint.

Llion Jones cowrote "Attention Is All You Need," the seminal paper that introduced the transformer — the architecture that launched the generative AI revolution. Now he warns that the industry that grew out of this breakthrough is stifling the next one. Learn why the current corporate arms race is killing true innovation and how we can get back to bold exploration.Learn more about our flagship conference happening this April at attend.ted.com/podcast Hosted on Acast. See acast.com/privacy for more information.

Join us on WOAFM99 for an explosive episode featuring a high-octane mix of WOA chart-toppers currently dominating the global scene and the freshest talent discovered by the WOA team. Today is a Certified Indie Songs of the Week episode, bringing you a curated selection of breakthrough artists from every corner of the globe. In addition to the incredible music, several WOA artists have sent in exclusive radio plugs specifically for our listeners, giving you a behind-the-scenes look at the people behind the hits. Hosted by Oliver Sean MTV EMA Nominee, Multiple Billboard Top 10 Artist & Producer, Grammy U Mentor, and Former MTV VJ. The Certified Indie & Breakthrough Lineup Boonville Bill Beach – Safe Keeping * Purusa – Fall Behind * The Cautious Arc – You're Gonna Want Me Back* Mia Rose Brake – Somersault * Jacques Pena – Je Suis Jaloux * Eggmen Road – I Never Want Our Past To Be Our Present * Mishell Ivon & Lowly Light – Impossible Possibility * Melyssa Lee with Education Party – Just Friends * Exit 13 Duo – Please Tell Her --- Artists: We are now accepting submissions for Season 31. To have your music considered for the show, please submit your tracks at woafm99.com. www.woaentertainment.com www.oliversean.com 

Bodies don't just wear down, they lose communication. What happens when that internal signal starts working again and hundreds of people suddenly experience dramatic turnarounds? I talk with Bobbi Vitality about a new wave of smart medicine, why documented testimonies are multiplying, and how faith and science are intersecting in unexpected ways. You'll come away seeing your body less as fragile and more as designed with restoration already built inside it.   Podcast Episode 2025: Smart Medicine Breakthroughs + 700 Recovery and Healing Testimonies | don't miss this! Listen to more episodes of the Lance Wallnau Show at lancewallnau.com/podcast

In this episode, we are joined by Ramesh Chandra, Director – Academics at the Language Learning Foundation (LLF). LLF is a leading non-profit organization working closely with government primary schools to strengthen FLN outcomes for children across India.Over the course of this 15-minute discussion, we explore the key barriers and practical solutions in implementing FLN at scale. The conversation delves into on-ground challenges, differences in learning levels between rural and urban settings, effective remedial strategies for slow learners, and real-life examples where focused FLN interventions have delivered measurable improvements.CreditsGuest: Ramesh ChandraHost: Shreya MResearch: Alisha CProduced by: The Good SightConcept: The Good SightFor feedback or to participate, write to us at ⁠contact@thegoodsight.org#FoundationalLiteracy #FoundationalNumeracy #FLN#EducationInIndia

What if your hardest moments aren't setbacks—but invitations to grow? In this powerful and deeply honest conversation, PowerWomen Podcast co-hosts Claire Brown and Gayatri Agnew sit down with activist, speaker, and storyteller Cara E Yar Khan to explore how heartbreak, identity, and discomfort shape our greatest breakthroughs.     From navigating personal loss to redefining strength, Cara shares profound insights on what she calls post-traumatic wisdom—and why sitting in the uncomfortable moments is often where transformation begins. Together, they unpack how faith, self-reflection, boundaries, and community support play essential roles in healing and rising stronger.     This episode is a reminder that you don't need to rush your healing—and that growth doesn't come from fixing, but from allowing. If you're moving through change, grief, or a season of uncertainty, this conversation will meet you right where you are.     ✨ Listen in for wisdom, reassurance, and permission to grow at your own pace.     POWERWOMEN LINKS:     WEBSITE: https://thepowerwomen.org/     LR FACEBOOK GROUP: https://www.facebook.com/groups/1807102609586780     NWA FACEBOOK GROUP: https://www.facebook.com/groups/www.thepowerwomen.org     INSTAGRAM: https://www.instagram.com/powerw.o.m.e.n     YOUTUBE: https://www.youtube.com/@PowerWomenPodcast     Podcast Produced by clantoncreative.com

Alpha Hour Exhortation – Episode 1225

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a range of stories that highlight the dynamic and often challenging landscape of these industries, as they navigate through scientific breakthroughs, strategic collaborations, regulatory hurdles, and market trends.Starting with corporate restructuring, Roche's Genentech has announced significant layoffs, totaling 489 positions in the previous year. This move is part of broader restructuring efforts seen across large pharmaceutical companies like Bayer and Bristol Myers Squibb. The layoffs illustrate the tightening financial and scientific constraints that are influencing pipeline decisions and capital allocation. Companies are facing increasing pressures to maintain credibility while also dealing with economic challenges that impact their strategic directions.On the regulatory front, the U.S. Department of Health and Human Services (HHS) encountered legal setbacks concerning its 340B rebate model pilot program. Following a lawsuit from the American Hospital Association, HHS withdrew notices and application approvals for this initiative. This development indicates a need for more comprehensive public feedback before any future attempts at similar programs are made, highlighting how complex regulatory landscapes can become.Turning to clinical trials, Fierce Biotech identified several significant failures in 2025, underscoring the inherent risks involved in drug development. These setbacks emphasize the importance of robust trial designs and execution strategies to mitigate risks. Meanwhile, Fresenius Kabi and Phlow Corporation have announced a strategic alliance to produce epinephrine injection API in the U.S., aiming to strengthen supply chain resilience—a crucial lesson learned from vulnerabilities exposed during the COVID-19 pandemic.Eli Lilly has made waves with its $2.4 billion acquisition of Orna Therapeutics, marking its entry into the in vivo CAR-T space. This acquisition underscores a growing interest in advanced cell therapies with transformative potential for cancer treatment. Additionally, Lilly has expanded its collaboration with Innovent Biologics through a $350 million upfront payment and milestone payments totaling $8.8 billion, focusing on oncology and immunology. This reflects a shift towards deeper integration in drug development efforts beyond traditional licensing models.Takeda Pharmaceuticals' $1.7 billion AI-driven drug discovery agreement with Iambic Therapeutics highlights the increasing adoption of artificial intelligence to accelerate drug discovery processes. AI's potential to enhance precision medicine approaches is becoming more pronounced as companies seek innovative methods to improve target identification and lead optimization.In market dynamics, Hims & Hers withdrew from launching a generic version of Novo Nordisk's weight loss pill due to regulatory pressures from the FDA. This incident underscores the complex interplay between innovation and compliance that companies must navigate when bringing new therapeutics to market. Additionally, legal actions have been initiated by Novo Nordisk against Hims & Hers over patent infringement claims related to semaglutide—a case highlighting ongoing challenges in patent protection within rapidly evolving drug compounding arenas.Eli Lilly also leveraged the global stage of the Winter Olympics for a campaign drawing parallels between scientific progress and athletic achievement. Such campaigns align with industry efforts to enhance public perception and trust amid ongoing challenges.Overall, while the pharmaceutical and biotech industries face significant challenges—from regulatory hurdles to clinical trial setbacks—there are substantial opportunities for growth driven by technological advancements and strategic collaborations. NaSupport the show

Wonder Woman is almost certainly one of the most enduring characters in all of pop culture. She's certainly the most famous female superhero of all time. But we would argue… The post e408. Wonder Woman: Boundaries, Bondage, and Breakthroughs appeared first on The VoxPopcast.

New series for the next seven weeks through the book of Nehemiah called burdens to breakthroughs and what it looks like to build space where people encounter God and experience grace. The message today is entitled broken with a burden, blessed with a breakthrough. So often we want the second without the first. I'm going to show you today and throughout this series the importance of the first part and the process it takes to get from burden to blessing.

TCL made one of the biggest impressions at CES this year, showcasing new television technology, massive screen sizes, advanced audio, portable projection, and emerging AR experiences.Marc Aflalo is joined by Bruce Walker, Product Evangelist at TCL, to break down everything announced at the show and what it means for consumers heading into 2026. From next-generation SQD Mini LED displays and record-setting brightness to 98-inch and 115-inch screen options becoming more accessible, TCL is pushing performance, scale, and value across the entire home entertainment lineup. The conversation also explores integrated Bang & Olufsen audio, Dolby FlexConnect wireless sound expansion, AI-powered picture and sound processing, and deeper Google Gemini integration designed to simplify how viewers discover and enjoy content. Beyond televisions, TCL highlights portable smart projectors, gaming-focused monitors, and augmented reality glasses that point toward the future of connected entertainment. Bruce shares how TCL's vertical integration, rapid product availability after CES, and leadership in large-screen and Mini LED categories are shaping the company's strategy for the North American market and positioning 2026 as a defining year for the brand. Subscribe for more conversations with the people building the future of technology, home entertainment, and innovation. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode of the ASC Podcast with John Goehle, we discuss the latest news in the industry, recent survey experiences, including a reminder about expiration dates, review 2025's profitability breakthroughs and in our focus segment we discuss Malignant Hyperthermia with Dr. Andrew Herlich This episode is sponsored by Surgical Information Systems, RFX Solutions, Medserve and  Ambulatory Healthcare Strategies.   Notes and Resources from this Episode: Beckers ASC review-- Most Profitable Breakthroughs in 2025: https://www.beckersasc.com/asc-transactions-and-valuation-issues/ascs-most-profitable-breakthroughs-in-2025/?origin=ASCE&utm_source=ASCE&utm_medium=email&utm_content=newsletter&oly_enc_id=5567B4088734C3Z Boston Bowel Prep Scale: https://www.endoscopy-campus.com/en/classifications/boston-bowel-preparation-scale/ INFORMATION ABOUT THE ASC PODCAST WITH JOHN GOEHLE ASC Central, a sister site to http://ascpodcast.com provides a link to all of our bootcamps, educational programs and membership programs! https://conferences.asc-central.com/ Join one of our Membership Programs! Our Patron Program: Patron Members of the ASC Podcast with John Goehle have access to ASC Central - an exclusive membership website that provides a one-stop  ASC Regulatory and Accreditation Compliance, Operations and Financial Management resource for busy Administrators, nurse managers and business office managers.  More information and Become Member The ASC-Central Premium Access Program A Premium Resource for Ambulatory Surgery Centers including access to bootcamps, education programs and private sessions More Information and Become a Premium Access Program Members Today! Important Resources for ASCs: Conditions for Coverage: https://www.ecfr.gov/cgi-bin/text-idx?c=ecfr&rgn=div5&view=text&node=42:3.0.1.1.3&idno=42#se42.3.416_150 Infection Control Survey Tool (Used by Surveyors for Infection Control) https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/downloads/som107_exhibit_351.pdf Updated Guidance for Ambulatory Surgical Centers - Appendix L of the State Operations Manual (SOM) https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/downloads/som107ap_l_ambulatory.pdf https://www.cms.gov/medicareprovider-enrollment-and-certificationsurveycertificationgeninfopolicy-and-memos-states-and/updated-guidance-ambulatory-surgical-centers-appendix-l-state-operations-manual-som Policy & Memos to States and Regions CMS Quality Safety & Oversight memoranda, guidance, clarifications and instructions to State Survey Agencies and CMS Regional Offices. https://www.cms.gov/Medicare/Provider-Enrollment-and-Certification/SurveyCertificationGenInfo/Policy-and-Memos-to-States-and-Regions Other Resources from the ASC Podcast with John Goehle: Visit the ASC Podcast with John Goehle Website Books by John Goehle Get a copy of John's most popular book - The Survey Guide - A Guide to the CMS Conditions for Coverage & Interpretive Guidelines for Ambulatory Surgery Centers 

God surely has reasons for waiting to give you the breakthrough you have sought for decades. Keep asking in hope.

For better AI agents, we just need bigger models, right?

"Get out of the mentality of seeking one-time breakthroughs. Get into the mentality of seeking ongoing permanence."  A breakthrough can feel powerful in the moment—but without reinforcement, it fades. Real change doesn't come from a single surge of motivation. It comes from building habits, structures, and support that hold the change in place.  Permanence is what turns insight into identity. When growth is supported over time, confidence stabilizes, progress compounds, and results stop collapsing back to where they started. Breakthroughs may spark the fire—but permanence is what keeps it burning.  Also in this episode:  Greg Stephens  Visit https://www.eCircleAcademy.com and book a success call with Nicky to take your practice to the next level. 

Tech in China is a new podcast from Everything Electric, offering an on-the-ground look at the fastest-moving technology ecosystem in the world. Hosted by Robert Llewellyn and China Correspondent Elliot Richards, the show takes a look at everything from humanoid robots working in "dark factories" and autonomous drones, to battery breakthroughs and the rise of the low-altitude economy.    Based in Shanghai, Elliot brings first-hand access to the companies and technologies reshaping the tech landscape. From viral robot demos to wind turbines the size of skyscrapers, Tech in China explains what's coming next and why it matters far beyond China.  @EverythingElectricShow   @everythingelectricapac   00:00 Welcome to Tech in China  04:30 China's Long Innovation Story  06:55 Humanoid Robots Get Real  11:40 When Robots Go Viral  14:30 Exoskeletons & an Ageing Society  17:45 The Battery Race: Sodium vs Solid State  23:00 The Low-Altitude Economy  30:45 EVs Enter the Survival Phase  38:30 The Centre of Gravity Shifts East   Why not come and join us at our next Everything Electric expo: www.everythingelectric.show  Support our StopBurningStuff campaign: https://www.patreon.com/STOPBurningStuff Become an Everything Electric Patreon: https://www.patreon.com/fullychargedshow Become a YouTube member: use JOIN button above Buy the Fully Charged Guide to Electric Vehicles & Clean Energy : https://buff.ly/2GybGt0 Subscribe for episode alerts and the Everything Electric newsletter: https://fullycharged.show/zap-sign-up/ Visit: https://FullyCharged.Show Find us on X: https://x.com/Everyth1ngElec Follow us on Instagram: https://instagram.com/officialeverythingelectric To partner, exhibit or sponsor at our award-winning expos email: commercial@fullycharged.show EE NORTH (Harrogate) - 8th & 9th May 2026  EE WEST (Cheltenham) - 12th & 13th June 2026  EE GREATER LONDON (Twickenham) - 11th & 12th Sept 2026   EE SYDNEY - Sydney Olympic Park - 18th - 20th Sept 2026   #fullychargedshow #everythingelectricshow #homeenergy #cleanenergy #battery #electriccars #electric-vehicles-uk #tech #china #electrification #humanoidrobot #robot #evtol

Jesse Karau of Slime & Slay Outdoors joins the Back Lash Podcast to share his Northwoods musky adventures, season highlights (including a 48-inch fish), and the family roots that shaped his fishing career. We cover tactics for windy and winter conditions, topwater and bucktail strategies, the M13 big-blade bait, solo-fishing tips, and where to find gear and content.

February 2026 is a pivotal month with a major shift from the practical, grounded energy of Capricorn into the innovative, breakthrough-oriented energy of Aquarius. As we enter a powerful six-week "eclipse portal," this month offers a rare opportunity for spiritual transformation, the shedding of old identities, and significant technological or social breakthroughs.Key Takeaways and Timestamps00:00 - The Three Phases of FebruaryFebruary is defined by three distinct stages: the onset of eclipse season, a massive shift into Aquarius energy alongside the Chinese New Year, and Mercury turning retrograde to close the month.01:08 - Identifying Your Personal FocusTo understand how these energies affect you, locate the house governed by Aquarius in your birth chart. This area of your life—whether it be career, relationships, or self—will receive the most attention and potential for breakthroughs this month.02:01 - Refining Rhythms and RoutinesUntil mid-February, utilize the remaining Capricorn influence to "tune up" your daily habits. Establishing sustainable morning rhythms and circadian-aligned routines sets the foundation for the growth to come.03:31 - The Full Moon in Cancer (Feb 1st)Starting the month with a full moon in the nakshatra of Ashlesha illuminates deep emotional needs and "stuck" energies. It is a time for addressing family, home stability, and finances.05:06 - Entering the Eclipse PortalEclipse season is a six-week window (starting early February through March 18th) that acts as a transformational portal.06:01 - Critical Dates: February 17th and March 3rdThese are the most intense days of the eclipse season. Avoid major decisions, big conversations, or starting new projects on these dates, as clarity will be low and obstacles are more likely.08:03 - Chinese New Year: The Fire HorseMid-month marks the transition from Snake energy into the Fire Horse. This shift brings forward momentum and a powerful "healing" energy through the Shatabhisha nakshatra, symbolized by "100 healers".09:47 - The Ego and Identity CrisisWith Ketu in Leo, you may experience a spiritual "death" or identity crisis. This is an opportunity to release old versions of yourself—like discarding worn-out clothes—to step into a more authentic power.18:01 - Mercury Retrograde in Pisces (Feb 26th)At the end of the month, Mercury turns retrograde and becomes "debilitated" in Pisces. From February 26th to March 20th, focus on cleaning, organizing, and finishing old projects rather than launching anything new.24:45 - Jupiter Retrograde: Returning to TeachersWith Jupiter retrograde in Gemini all month, it is an ideal time to reread influential books, reconnect with old mentors, and revisit past spiritual teachings.KEYWORDSVedic astrology forecast, February 2026 astrology, eclipse season, Aquarius stellium, Mercury retrograde Pisces, Rahu Ketu, Jyotish, spiritual growth, identity shifts, Jeremy Devens, Horoscope, SiderealFREE RESOURCES at https://www.quietmindastrology.com⭐️ Free Birth Chart⭐️ Free Horoscopes⭐️ Podcast⭐️ Instagram⭐️ YouTubeWORK WITH ME⭐️ Book a Reading⭐️ Decode Your Chart⭐️ Mentorship